BBa_B1006
1
BBa_B1006
Terminator (artificial, large, %T~>90)
2006-08-30T11:00:00Z
2015-08-31T04:07:21Z
modified E. coli thr terminator, replaced all A-T pairs in stem with C-G pairs
Released HQ 2013
Artificial terminator, estimated %T~>90%
*8bp stem, 6nt loop
*Bidirectional, estimated reverse %T~>90%
false
true
_41_
0
745
41
In stock
false
Bidirectional, with the reverse estimated to be less effective than the forward. Has a polyA tail of 9 residues.
true
Haiyao Huang
annotation1898430
1
PolyA
range1898430
1
32
39
annotation1898428
1
B1006
range1898428
1
1
39
annotation1898431
1
PolyA
range1898431
1
1
9
annotation1898429
1
modified thr terminator
range1898429
1
10
31
BBa_M39111
1
BBa_M39111
Vector for creation of micro-dystrophin SFV
2012-05-14T11:00:00Z
2015-05-08T01:14:07Z
This part came from a combination of a portion of the SFV genome, in addition to the micro-dystrophin genomic sequence and standard promoters and terminator.
Released HQ 2013
The general purpose of our part is to help create a modified Semliki Forest Virus that contains micro-dystrophin mRNA in its capsid, which hopefully will be used to deliver said mRNA to muscle cells of muscular dystrophy patients. This DNA vector contains an RNA polymerase promoter, the packaging sequence from SFV (Semliki Forest Virus), the DNA sequence for micro-dystrophin, and an RNA polymerase terminator (Bba_B1006). Once this vector is transcribed into RNA in vitro, the resultant RNA is introduced into a cell in the lab. A separate helper vector (not included in this part) will be introduced into the same cell as well. This other vector will simply contain the genes for the structural proteins of SFV. Once the helper vector is translated to produce the structural capsid proteins, the virus will assemble within the cell, packaging the micro-dystrophin mRNA within the capsid of the virus. The purpose of removing the non-structural genes (other than the necessary packaging sequence) is to remove the replicating and virulent ability of the virus, so that it will not replicate within the body. This virus will then break free of the cell in which it was produced, at which point it can be harvested and injected into patients to treat dystrophin deficiency within muscle cells.
true
false
_1206_
0
13167
9
Discontinued
false
We had to make sure only to include the packaging sequences of SFV, so that it would not be able to replicate within the patient's cells. This should also reduce the virulent capabilities of the virus.
false
Hannah Kempton
annotation2175190
1
modified thr terminator
range2175190
1
10
31
annotation2175192
1
BBa_B1006
range2175192
1
1
39
annotation2175189
1
PolyA
range2175189
1
1
9
annotation2175188
1
B1006
range2175188
1
1
39
annotation2175191
1
PolyA
range2175191
1
32
39
BBa_M39111_sequence
1
aaaaaaaaaccccgcccctgacagggcggggtttttttt
BBa_B1006_sequence
1
aaaaaaaaaccccgcccctgacagggcggggtttttttt
igem2sbol
1
iGEM to SBOL conversion
Conversion of the iGEM parts registry to SBOL2.1
James Alastair McLaughlin
Chris J. Myers
2017-03-06T15:00:00.000Z